Bempedoic acid

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 319651

CAS#: 738606-46-7

Description: Bempedoic acid, also known as ESP-55016 and ETC-1002, is an orally available, once-daily LDL-C lowering small molecule designed to lower elevated levels of LDL-C and to avoid side effects associated with existing LDL-C lowering therapies. Bempedoic acid is absorbed rapidly in the small intestine and enters the liver through cell surface receptors different from those transporters that selectively take up statins. Bempedoic acid is a regulator of lipid and carbohydrate metabolism.

Price and Availability


USD 250
USD 950
USD 4450

USD 450
USD 1450

USD 750
USD 2450

Bempedoic acid, purity > 98%, is in stock. The same day shipping after order received.

Chemical Structure


Theoretical Analysis

MedKoo Cat#: 319651
Name: Bempedoic acid
CAS#: 738606-46-7
Chemical Formula: C19H36O5
Exact Mass: 344.2563
Molecular Weight: 344.492
Elemental Analysis: C, 66.25; H, 10.53; O, 23.22

Synonym: ESP-55016; ESP55016; ESP 55016; ETC-1002; ETC 1002; ETC1002; Bempedoate; Bempedoic acid

IUPAC/Chemical Name: 8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid


InChi Code: InChI=1S/C19H36O5/c1-18(2,16(21)22)13-9-5-7-11-15(20)12-8-6-10-14-19(3,4)17(23)24/h15,20H,5-14H2,1-4H3,(H,21,22)(H,23,24)


Technical Data

Solid powder

>98% (or refer to the Certificate of Analysis)

Safety Data Sheet (MSDS):

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Soluble in DMSO, not in water

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:


1: Lemus HN, Mendivil CO. Adenosine triphosphate citrate lyase: Emerging target in the treatment of dyslipidemia. J Clin Lipidol. 2015 May-Jun;9(3):384-9. doi: 10.1016/j.jacl.2015.01.002. Epub 2015 Jan 14. Review. PubMed PMID: 26073398.

2: Thompson PD, Rubino J, Janik MJ, MacDougall DE, McBride SJ, Margulies JR, Newton RS. Use of ETC-1002 to treat hypercholesterolemia in patients with statin intolerance. J Clin Lipidol. 2015 May-Jun;9(3):295-304. doi: 10.1016/j.jacl.2015.03.003. Epub 2015 Mar 19. PubMed PMID: 26073387.

3: Nikolic D, Mikhailidis DP, Davidson MH, Rizzo M, Banach M. ETC-1002: a future option for lipid disorders? Atherosclerosis. 2014 Dec;237(2):705-10. doi: 10.1016/j.atherosclerosis.2014.10.099. Epub 2014 Oct 31. Review. PubMed PMID: 25463109.

4: Filippov S, Pinkosky SL, Newton RS. LDL-cholesterol reduction in patients with hypercholesterolemia by modulation of adenosine triphosphate-citrate lyase and adenosine monophosphate-activated protein kinase. Curr Opin Lipidol. 2014 Aug;25(4):309-15. doi: 10.1097/MOL.0000000000000091. Review. PubMed PMID: 24978142; PubMed Central PMCID: PMC4162331.

5: Goldberg R. Targeting low-density lipoprotein and dysmetabolism in type 2 diabetes mellitus. Arterioscler Thromb Vasc Biol. 2014 Mar;34(3):477-8. doi: 10.1161/ATVBAHA.114.303171. PubMed PMID: 24554605; PubMed Central PMCID: PMC4067598.

6: Gutierrez MJ, Rosenberg NL, Macdougall DE, Hanselman JC, Margulies JR, Strange P, Milad MA, McBride SJ, Newton RS. Efficacy and safety of ETC-1002, a novel investigational low-density lipoprotein-cholesterol-lowering therapy for the treatment of patients with hypercholesterolemia and type 2 diabetes mellitus. Arterioscler Thromb Vasc Biol. 2014 Mar;34(3):676-83. doi: 10.1161/ATVBAHA.113.302677. Epub 2014 Jan 2. PubMed PMID: 24385236.

7: Ballantyne CM, Davidson MH, Macdougall DE, Bays HE, Dicarlo LA, Rosenberg NL, Margulies J, Newton RS. Efficacy and safety of a novel dual modulator of adenosine triphosphate-citrate lyase and adenosine monophosphate-activated protein kinase in patients with hypercholesterolemia: results of a multicenter, randomized, double-blind, placebo-controlled, parallel-group trial. J Am Coll Cardiol. 2013 Sep 24;62(13):1154-62. doi: 10.1016/j.jacc.2013.05.050. Epub 2013 Jun 13. PubMed PMID: 23770179.

8: Kane JP. New horizons in lipid management. J Am Coll Cardiol. 2013 Sep 24;62(13):1163-4. doi: 10.1016/j.jacc.2013.05.052. Epub 2013 Jun 13. PubMed PMID: 23770169.

9: Filippov S, Pinkosky SL, Lister RJ, Pawloski C, Hanselman JC, Cramer CT, Srivastava RA, Hurley TR, Bradshaw CD, Spahr MA, Newton RS. ETC-1002 regulates immune response, leukocyte homing, and adipose tissue inflammation via LKB1-dependent activation of macrophage AMPK. J Lipid Res. 2013 Aug;54(8):2095-108. doi: 10.1194/jlr.M035212. Epub 2013 May 24. PubMed PMID: 23709692; PubMed Central PMCID: PMC3708360.

10: Norata GD, Ballantyne CM, Catapano AL. New therapeutic principles in dyslipidaemia: focus on LDL and Lp(a) lowering drugs. Eur Heart J. 2013 Jun;34(24):1783-9. doi: 10.1093/eurheartj/eht088. Epub 2013 Mar 18. Review. PubMed PMID: 23509227; PubMed Central PMCID: PMC3857929.

11: Pinkosky SL, Filippov S, Srivastava RA, Hanselman JC, Bradshaw CD, Hurley TR, Cramer CT, Spahr MA, Brant AF, Houghton JL, Baker C, Naples M, Adeli K, Newton RS. AMP-activated protein kinase and ATP-citrate lyase are two distinct molecular targets for ETC-1002, a novel small molecule regulator of lipid and carbohydrate metabolism. J Lipid Res. 2013 Jan;54(1):134-51. doi: 10.1194/jlr.M030528. Epub 2012 Nov 1. PubMed PMID: 23118444; PubMed Central PMCID: PMC3520520.